Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2885.1992.tb00992.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diverse Drug Classes Partition into Human Sweat: Implications for Both Sweat Fundamentals and for Therapeutic Drug Monitoring.
Ther Drug Monit
December 2023
Eccrine Systems, Inc., Cincinnati, Ohio.
Therapeutic drug monitoring to optimize drug therapy typically relies on the inconvenience of repeated plasma sampling. Sweat is a potential alternative biofluid convenient for sampling. However, limited information exists regarding the range of drugs excreted in sweat and their correlation with plasma concentrations.
View Article and Find Full Text PDFIdentifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection.
Clin Pharmacol Ther
November 2022
Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Methadone and buprenorphine have pharmacologic properties that are concerning for a high risk of drug-drug interactions (DDIs). We performed high-throughput screening for clinically relevant DDIs with methadone or buprenorphine by combining pharmacoepidemiologic and pharmacokinetic approaches. We conducted pharmacoepidemiologic screening via a series of self-controlled case series studies (SCCS) in Optum claims data from 2000 to 2019.
View Article and Find Full Text PDFInhibition of In Vitro Metabolism of Opioids by Skeletal Muscle Relaxants.
Basic Clin Pharmacol Toxicol
September 2018
Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA.
The purpose of this study was to test the hypothesis that skeletal muscle relaxants could inhibit the in vitro metabolism of common comedications opioids buprenorphine, methadone and oxycodone. The compounds [solubility-limited concentration (μM) studied] were as follows: baclofen (1000), carisoprodol (200), its metabolite meprobamate (1000), chlorzoxazone (200), cyclobenzaprine (1000), metaxalone (50), methocarbamol (1000), orphenadrine (1000) and tizanidine (1000). Compounds were first incubated with human liver microsomes ± pre-incubation, screened with pathway-specific cDNA-expressed cytochrome P450s (rCYP), and then IC values determined using either 8-concentration tests for those where the rCYP screen suggested an IC was achievable, or a 3-concentration test with downward extrapolation if screen suggested 50% inhibition was not achievable.
View Article and Find Full Text PDFPharmacokinetics of methocarbamol and phenylbutazone in exercised Thoroughbred horses.
J Vet Pharmacol Ther
October 2016
Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, CA, USA.
Methocarbamol (MCBL) is commonly used in performance horses for the treatment of skeletal muscle disorders. Current regulatory recommendations for show horses and racehorses are based on a single oral dose of 5 g, although doses in excess of this are often administered. The goal of the current study was to characterize the disposition of MCBL following higher dose administration and administration in combination with another commonly used drug in performance horses, phenylbutazone (PBZ).
View Article and Find Full Text PDFSimultaneous determination of paracetamol and methocarbamol in human plasma By HPLC using UV detection with time programming: application to pharmacokinetic study.
Drug Res (Stuttg)
July 2014
Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
Background: A combination of methocarbamol (MET) and paracetamol (PAR) is a widely used treatment approach. It provides complementary modes of action for treatment of pain associated with muscle spasm. The aim of this work was to develop and validate a new sensitive and reproducible isocratic reversed phase HPLC-UV detection method for simultaneous determination of MET and PAR in human plasma for the routine use in a therapeutic drug monitoring and pharmacokinetic laboratories.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!